Emergent BioSolutions | EBS - Capital De Empréstimo





Capital De Empréstimo Alterar Data
Acadia Pharmaceuticals USD 0 0 2025-03
Akebia Therapeutics USD 24.75M 11.64M 2026-06
ALKERMES USD 1.48B 7.23M 2026-06
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
ANI Pharmaceuticals USD 280.15M 5.84M 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Coherus Biosciences USD 51.08M 496K 2025-12
Emergent BioSolutions USD 446.5M 1.7M 2023-12
Glaxosmithkline GBP 18.53B 1.29B 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Ionis Pharmaceuticals USD 1.91B 6.62M 2026-06
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Lexicon Pharmaceuticals USD 49.68M 276K 2026-03
Lonza CHF 3.88B 323M 2025-12
Merck USD 51.08B 4.41B 2026-06
Moderna USD 597M 6M 2026-06
Myriad Genetics USD 120.7M 400K 2026-06
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
Pacira USD 363.12M 4.53M 2026-06
Pfizer USD 60.5B 70M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Sanofi EUR 14.65B 806M 2026-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12